Global Systemic Psoriasis Therapeutics Market 2018-2022

Want to know what type of information to expect from this report? The infographic below contains a selection of facts about systemic treatment of psoriasis. Find out more below!

The global systemic psoriasis therapeutics market is expected to expand at a CAGR of more than 10% during the forecast period

Systemic psoriasis therapeutics industry growth is expected to accelerate over the next five years, driven by countries around the world. While the Americas will drive the largest growth of over 63%, EMEA and APAC are also expected to make significant contributions to the incremental growth in the forecast period. The Americas held the largest market share in 2017, followed by EMEA and APAC. The Americas are forecasted to expand their market share during the period of forecast, however, EMEA and APAC region is expected to witness a decline during the next five years owing to the high influx of generic drugs available in countries like India and China. Technavio’s systemic psoriasis therapeutics industry analysis reveals promising markets around the world.

Want a bigger picture? Try a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Growing need for affordable systemic treatment for psoriasis is a major factor driving the market

The systemic psoriasis therapeutics market is driven by an increasing need for affordable options for the treatment of psoriasis. The most often purchased medication for systemic treatment of psoriasis are topical treatments. The cost of treatment of psoriasis largely depends on the type of therapy used, namely topical, systemic, or phototherapy. Although the rate of hospitalization is low for psoriasis, however, patients affected with psoriasis are compelled to spend heavily on medical expenses as the disease is closely linked to many comorbidities such as diabetes, obesity, malignancies, hypertension, CVDs, and psoriatic arthritis.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services.      Start your 14-day FREE trial

AbbVie, Amgen, and Celgene are among the leading vendors in the systemic psoriasis therapeutics market

As the market continues to flourish, it is growing very highly concentrated with the existence of many well-established large players and regional vendors that offer systemic treatment for psoriasis. The first line of treatment of psoriasis is generally a systemic agent with or without the use of topical agent and phototherapy. In the case of the systemic treatment for psoriasis being inadequate or ineffective, agents with higher potency are used which end up driving up the medical costs. It has been observed that patients have the tendency to develop resistance to monotherapy drugs over a period of time, which results in the adoption of combination therapy. Combination therapy is known to fight psoriasis on multiple fronts, which enhances the total effect of the systemic treatment of psoriasis. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their competitors.

This report offers a complete analysis of several companies, including:

• AbbVie
• Amgen
• Celgene
• Johnson & Johnson

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements.     Get in touch